| アブストラクト | Vaccine development against COVID-19 has mitigated severe disease. However, reports of rare but serious adverse events following immunization (sAEFI) in the young populations are fuelling parental anxiety and vaccine hesitancy. With a very early season of viral illnesses including COVID-19, respiratory syncytial virus (RSV), influenza, metapneumovirus and several others, children are facing a winter with significant respiratory illness burdens. Yet, COVID-19 vaccine and booster uptake remain sluggish due to the mistaken beliefs that children have low rates of severe COVID-19 illness as well as rare but severe complications from COVID-19 vaccine are common. In this study we examined composite sAEFI reported in association with COVID-19 vaccines in the United States (US) amongst 5-17-year-old children, to ascertain the composite reported risk associated with vaccination. Between December 13, 2020, and April 13, 2022, a total of 467,890,599 COVID-19 vaccine doses were administered to individuals aged 5-65 years in the US, of which 180 million people received at least 2 doses. In association with these, a total of 177,679 AEFI were reported to the Vaccine Adverse Event reporting System (VAERS) of which 31,797 (17.9%) were serious. The rates of ED visits per 100,000 recipients were 2.56 (95% CI: 2.70-3.47) amongst 5-11-year-olds, 18.25 (17.57-18.95) amongst 12-17-year-olds and 33.74 (33.36-34.13) amongst 18-65-year olds; hospitalizations were 1.07 (95% CI 0.87-1.32) per 100,000 in 5-11-year-olds, 6.83 (6.42-7.26) in 12-17-year olds and 8.15 (7.96-8.35) in 18-65 years; life-threatening events were 0.14 (95% CI: 0.08-0.25) per 100,000 in 5-11-year olds, 1.22 (1.05-1.41) in 12-17-year-olds and 2.96 (2.85-3.08) in 18-65 year olds; and death 0.03 (95% CI 0.01-0.10) per 100,000 in 5-11 year olds, 0.08 (0.05-0.14) amongst 12-17-year olds and 0.76 (0.71-0.82) in 18-65 years age group. The results of our study from national population surveillance data demonstrate rates of reported serious AEFIs amongst 5-17-year-olds which appear to be significantly lower than in 18-65-year-olds. These low risks must be taken into account in overall recommendation of COVID-19 vaccination amongst children. |
|---|
| ジャーナル名 | PloS one |
|---|
| Pubmed追加日 | 2023/2/18 |
|---|
| 投稿者 | Mangat, Halinder S; Rippon, Brady; Reddy, Nikita T; Syed, Akheel A; Maruthanal, Joel M; Luedtke, Susanne; Puthumana, Jyothy J; Srivatsa, Abhinash; Bosman, Arnold; Kostkova, Patty |
|---|
| 組織名 | Department of Neurology, University of Kansas Medical Center, Kansas City,;Kansas, United States of America.;Department of Population Health Sciences, Weill Cornell Medical College, New;York, New York, United States of America.;Department of Medical Sciences, Newcastle University, Great Britain, Newcastle;upon Tyne, United Kingdom.;Faculty of Biology Medicine and Health, The University of Manchester, Manchester,;United Kingdom.;Gesundheitsamt Nuremberg, Nuremberg, Germany.;Department of Cardiology, Northwestern Medicine, Chicago, Illinois, United States;of America.;Department of Pediatrics, Boston's Children's Hospital, Boston, Massachusetts,;United States of America.;Transmissible BV, Public Health Learning Solutions, Utrecht, The Netherlands.;UCL Centre for Public Health in Emergencies (dPHE), University College London,;London, United Kingdom. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36800368/ |
|---|
